Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/28/2003CA2404045A1 Use of coagulation factor vii-activating protease for the prophylaxis and therapy of vasoproliferative disorders
03/27/2003WO2003029411A2 Novel cyclooxygenase variants and methods of use
03/27/2003WO2003025542A2 Immune response associated proteins
03/27/2003WO2003025199A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor
03/27/2003WO2003025188A1 Use of a lentiviral vector in the treatment of pain
03/27/2003WO2003025178A1 Novel protein and dna thereof
03/27/2003WO2003025177A2 Sequences involved in phenomena of tumour suppression, tumour reversion, adoptosis and/or resistance to viruses and the use thereof as medicaments
03/27/2003WO2003025149A2 Cell populations which co-express cd49c and cd90
03/27/2003WO2003025131A2 Protein modification and maintenance molecules
03/27/2003WO2003025130A2 Receptors and membrane-associated proteins
03/27/2003WO2003025129A2 Neurotransmission-associated proteins
03/27/2003WO2003025014A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies
03/27/2003WO2003024993A2 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
03/27/2003WO2003024976A2 Tricyclic indole derivatives as 5-ht ligands
03/27/2003WO2003024972A1 New oripavine derivatives and their uses as medicines
03/27/2003WO2003024968A1 7-tert-butyl-3-(2-fluorophenyl)-6-(2h-(1,2,4)triazol-3-ylmethoxy)-(1,2,4)triazolo (4,3-b) pyridazine for the treatment of anxiety and convulsions
03/27/2003WO2003024966A1 Pteridinone derivatives as modulators of chemokine receptor activity
03/27/2003WO2003024964A1 Tricyclic pyridin-2-one analogues as gaba-a receptor ligands
03/27/2003WO2003024960A1 Novel use of substituted aminomethyl chromans
03/27/2003WO2003024955A2 Small molecule inhibitors of caspases
03/27/2003WO2003024953A1 Propanolamine derivative having 1,4-benzodioxane ring
03/27/2003WO2003024935A2 Substituted pyrazolyl compounds for the treatment of inflammation
03/27/2003WO2003024928A2 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
03/27/2003WO2003024485A1 REMEDIES FOR DISEASES CAUSED BY β-AMYLOIDS CONTAINING 2-100β INHIBITOR AS THE ACTIVE INGREDIENT
03/27/2003WO2003024479A1 Enamel matrix protein compositions for modulating immune response
03/27/2003WO2003024478A1 Treatment of central nervous system disorders by use of pdgf or vegf
03/27/2003WO2003024474A2 Anti-inflammatory agent
03/27/2003WO2003024472A2 Prolactin induced increase in neutral stem cell numbers and therapeutical use thereof
03/27/2003WO2003024471A2 Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
03/27/2003WO2003024464A1 Pharmaceutical composition containing valerina officinalis extract
03/27/2003WO2003024457A1 Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
03/27/2003WO2003024453A1 Excitatory amino acid receptor antagonists
03/27/2003WO2003024439A1 Phenethanolamine derivatives for treatment of respiratory diseases
03/27/2003WO2003024434A2 Use of a superoxide dismutase mimetic catalyst in the manufacture of a medicament for preventing and treating hiv-mediated central nervous system damage
03/27/2003WO2003024423A1 Apoptosis-mimicking synthetic entities and use thereof in medical treatment
03/27/2003WO2003024419A2 Apoptosis-mimicking natural vesicles and use thereof in medical treatment
03/27/2003WO2003024406A2 Nestin-expressing hair follicle stem cells
03/27/2003WO2003024397A2 Enhancement of learning and memory and treatment of amnesia
03/27/2003WO2003024395A2 Linked biaryl compounds
03/27/2003WO2003024393A2 Autologous t-cell vaccines materials and method
03/27/2003WO2003024360A1 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
03/27/2003WO2003024357A2 Microfabricated nanopore device for sustained release of therapeutic agent
03/27/2003WO2003024206A1 Psammomys obesus as an animal model for behavioural conditions
03/27/2003WO2003002553A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
03/27/2003WO2003002058A8 Bone anabolic compounds and methods of use
03/27/2003WO2002100352A3 Nr2b receptor antagonists for the treatment or prevention of migraines
03/27/2003WO2002094263A3 Caspase inhibitors and uses thereof
03/27/2003WO2002094254A3 Abuse resistant pharmaceutical composition containing capsaicin
03/27/2003WO2002091990A3 Prevention of addiction in pain management
03/27/2003WO2002088330A8 Neural progenitor cells
03/27/2003WO2002087496A3 Methods for inhibiting macrophage colony stimulating factor and c-fms-dependent cell signaling
03/27/2003WO2002083870A3 Pufa polyketide synthase systems and uses thereof
03/27/2003WO2002060859A3 Cyclic derivatives as modulators of chemokine receptor activity
03/27/2003WO2002055681A3 Regulation of human tau-tubulin kinase
03/27/2003WO2002053100A3 Pharmaceutical dosage form for oral administration of low molecular weight heparin
03/27/2003WO2002052019A3 22437, a human sulfatase and uses therefor
03/27/2003WO2002043738A3 Use of bisphosphonates for pain treatment
03/27/2003WO2002040508A3 Lactam dipeptide and its use in inhibiting beta-amyloid peptide release
03/27/2003WO2002040506A3 Modified clostridial neurotoxins with altered biological persistence
03/27/2003WO2002029060A3 Hematopoietin receptors hpr1 and hpr2
03/27/2003WO2002026774A3 Melanocortin receptor ligands
03/27/2003WO2002022684A3 Transporters and ion channels
03/27/2003WO2002016585A3 Imidazoline receptor homologs
03/27/2003WO2002015932A9 Methods for treating demyelinating diseases
03/27/2003WO2002012340A3 Transporters and ion channels
03/27/2003WO2001092218A3 Polyamine analogues as therapeutic and diagnostic agents
03/27/2003WO2001090109A9 Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
03/27/2003US20030060873 Providing an electrochemical solution comprising metal and bioactive material; contacting electrochemical solution and substrate; forming a bioactive composite structure on substrate using an electrochemical procedure
03/27/2003US20030060640 Cyanation of 1-(4-fluorophenyl)-1,3-dihydroisobenzo-furan for producing antidepressant citalopram
03/27/2003US20030060624 Reacting 2-chloro-4- trifluoromethyl-phenyl)-acetonitrile in the presence of a palladium catalyst and a base to form indene derivative
03/27/2003US20030060619 Antibody for use in the disgnosis and treatment of kidney, urogenital, and sex disorders
03/27/2003US20030060616 Type II IL-1 receptors
03/27/2003US20030060498 5-arylsulfonyl indoles useful for treating disease
03/27/2003US20030060497 Use of indole Mannich bases in the production of medicaments that are used to treat pain
03/27/2003US20030060493 Kit comprising a pharmaceutical composition containing repinotan or a physiologically acceptable salt of repinotan, and a means for the determination of the concentration of repinotan or its metabolites in body
03/27/2003US20030060487 Useful for treatments for peptide aggregation associated with disease state such as Alzhemimer's diseases
03/27/2003US20030060481 The use of scopolamine salts
03/27/2003US20030060478 Treatment of dyskinesia
03/27/2003US20030060470 Ortho, ortho-substituted nitrogen-containing bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparation comprising them
03/27/2003US20030060467 Substituted pyrazolo(1,5-d)(1,2,4)triazine derivatives, possessing a substitued or nonsubstituted cycloalkyl, phenyl or heteroaryl substituent at 7-position, an alkyl at 4-position, substituted alkoxy at 2-position; antianxiolytic
03/27/2003US20030060466 Such as 6-(4-(4-Fluoro-phenyl)-piperazin-1-yl)-2-methyl-5-nitro-3-(2,2,2-trifluoro -ethyl)-3H-pyrimidin-4-one, which are metabotropic glutamate receptor antagonists useful in treating psychological disorders
03/27/2003US20030060464 Therapeutic 1H-pyrido [ 4, 3-b ] indoles
03/27/2003US20030060462 Therapeutic compounds
03/27/2003US20030060458 Indoles and indolines having 5-HT activity
03/27/2003US20030060455 Treating lung damage from smoke, endometriosis, Behcet's disease, ankylosing spondylitis, cancer, Lyme disease, and/or restenosis following agioplasty with 1-(4-t-butyl-phenyl)-3-(4-(6-morpholin-4-ylmethyl-peperidin-yl)naphthalen-1 -yl)-urea
03/27/2003US20030060452 N-heterocyclic derivatives as NOS inhibitors
03/27/2003US20030060436 Treatment of parkinson's disease with oligonucleotides
03/27/2003US20030060423 Using cyclohexyl or pyran methylenesulfamate derivatives to treat psychological disorders
03/27/2003US20030060410 Use of HMG fragments as anti-inflammatory agents
03/27/2003US20030060403 Hepatocyte growth factor manufactured by gene recombination; treatment of dementia, senile dementia of Alzheimer type, cerebral stroke, and cerebral infarction
03/27/2003US20030060401 Genetic engineered drug
03/27/2003US20030060400 A modified nucleoside comprising a purine or pyrimidine ring for treating viral infections
03/27/2003US20030060399 A heat shock protein 20 (HSP20)-derived polypeptides for treating or inhibiting smooth muscle vasospasm, smooth muscle cell proliferation, migration, and vasoconstriction
03/27/2003US20030060397 Method of treating and preventing acute neural lesions with substances that modulate the expression or function of a protein involved in the cell cycle and pharmaceutical preparations containing such substances
03/27/2003US20030059938 Presenilin-deficient multipotent cell lines and screening methods for intramembrane-regulated proteolytic activities using these lines
03/27/2003US20030059916 IRAK-4: compositions and methods of use
03/27/2003US20030059871 Hematopoietin receptors HPR1 and HPR2
03/27/2003US20030059862 Antibodies against tumor necrosis factor delta (APRIL)
03/27/2003US20030059859 Vertebrate protein for use in human therapeutic and diagnostics
03/27/2003US20030059856 Detection of modulator of receptor binding activity; obtain sample containing receptor, incubate with test agent and ligand, monitor binding activity of ligand, adjusment in binding activity indicates modulator
1 ... 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 ... 1833